Cargando…

P2Y(12) Inhibitor Monotherapy after Percutaneous Coronary Intervention

In patients with acute and chronic coronary artery disease undergoing percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) has been the cornerstone of pharmacotherapy for the past two decades. Although its antithrombotic benefit is well established, DAPT is associated with an i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Xuan, Angiolillo, Dominick J., Ortega-Paz, Luis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604207/ https://www.ncbi.nlm.nih.gov/pubmed/36286292 http://dx.doi.org/10.3390/jcdd9100340

Ejemplares similares

P2Y12 blocker monotherapy after percutaneous coronary intervention
por: Verheugt, F. W. A., et al.
Publicado: (2021)

The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention
por: Luo, Liman, et al.
Publicado: (2019)

Tailoring P2Y(12) Inhibiting Therapy in Elderly Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Capranzano, Piera, et al.
Publicado: (2019)

P2Y12 Inhibitor Monotherapy with Clopidogrel versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Chen, Po-Wei, et al.
Publicado: (2020)

Editorial: Precision medicine for antithrombotic therapy in patients after percutaneous coronary interventions
por: Galli, Mattia, et al.
Publicado: (2023)

P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials
por: Sotomi, Yohei, et al.
Publicado: (2023)

P2Y12 Inhibitor Monotherapy versus Conventional Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Meta-Analysis
por: Feng, Wen-Han, et al.
Publicado: (2023)

Sex-Based Outcomes of P2Y12 Inhibitor Monotherapy After Three Months of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention
por: Shin, Eun-Seok, et al.
Publicado: (2023)

Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use
por: Capodanno, Davide, et al.
Publicado: (2019)

P2Y(12) inhibitor monotherapy in complex percutaneous coronary intervention: A post-hoc analysis of SMART-CHOICE randomized clinical trial
por: Roh, Ji Woong, et al.
Publicado: (2021)

De-escalation of P2Y12 Inhibitor Use After Percutaneous Coronary Intervention and Acute Coronary Syndromes
por: Barry, Quinton, et al.
Publicado: (2021)

Intolerance to Multiple P2Y12 Inhibitors Following Percutaneous Coronary Intervention
por: Shnoda, Mina, et al.
Publicado: (2021)

P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials
por: Valgimigli, Marco, et al.
Publicado: (2021)

Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention
por: Feng, Wen-Han, et al.
Publicado: (2022)

Multifaceted Intervention to Improve P2Y12 Inhibitor Adherence After Percutaneous Coronary Intervention: A Stepped Wedge Trial
por: Ho, P. Michael, et al.
Publicado: (2022)

Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention
por: Song, Kai, et al.
Publicado: (2022)

De-Escalation of P2Y(12) Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention
por: Kupka, Danny, et al.
Publicado: (2018)

Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention
por: Kumar, Arun, et al.
Publicado: (2022)

P2Y(12) Platelet Receptors: Importance in Percutaneous Coronary Intervention
por: Falcão, Felipe Jose de Andrade, et al.
Publicado: (2013)

P2y(12) inhibitor monotherapy after 1–3 months dual antiplatelet therapy in patients with coronary artery disease and chronic kidney disease undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials
por: Yu, Yanqiao, et al.
Publicado: (2023)

Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease
por: Cavallari, Ugo, et al.
Publicado: (2007)

When Less Becomes More: Insights on the Pharmacodynamic Effects of Aspirin Withdrawal in Patients With Potent Platelet P2Y(12) Inhibition Induced by Ticagrelor
por: Capodanno, Davide, et al.
Publicado: (2020)

Stroke After Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention: Incidence, Pathogenesis, and Outcomes
por: Gaudino, Mario, et al.
Publicado: (2019)

Safety of cangrelor and transition to oral P2Y(12) inhibitors in patients undergoing percutaneous coronary intervention: the ARCANGELO study
por: De Luca, Leonardo, et al.
Publicado: (2023)

Analysis of the Financial Impact of Using Cangrelor on the Safety and Efficacy Outcomes in Patients Undergoing Percutaneous Coronary Intervention in Whom Oral Therapy with P2Y(12) Inhibitors is Not Feasible or Desirable, in Spain
por: Lizano-Díez, Irene, et al.
Publicado: (2021)

Clinical Utility of Pharmacogene Panel‐Based Testing in Patients Undergoing Percutaneous Coronary Intervention
por: El Rouby, Nihal, et al.
Publicado: (2020)

Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention
por: Cavallari, Larisa H., et al.
Publicado: (2018)

P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials
Publicado: (2022)

Long-term Outcomes of Clopidogrel Monotherapy versus Prolonged Dual Antiplatelet Therapy beyond 12 Months after Percutaneous Coronary Intervention in High-risk Patients
por: Kim, Dong-Yeon, et al.
Publicado: (2021)

Coronavirus Disease 2019–Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management
por: Ortega‐Paz, Luis, et al.
Publicado: (2021)

Risk of ischaemic and haemorrhagic stroke in Chinese undergoing percutaneous coronary intervention treated with potent P2Y12 inhibitor versus clopidogrel
por: Ng, Andrew Kei-Yan, et al.
Publicado: (2022)

Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial
por: Johnson, Thomas W., et al.
Publicado: (2020)

Real-World Bleeding and Ischemic Events in Asian Patients on P2Y12-Inhibitors After Percutaneous Coronary Intervention: A National Claims Data Analysis
por: Lee, Yonggu, et al.
Publicado: (2020)

Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry
por: Tscharre, Maximilian, et al.
Publicado: (2017)

Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta‐Analysis
por: Gelbenegger, Georg, et al.
Publicado: (2021)

Cost-Effectiveness of Clopidogrel vs Aspirin Monotherapy After Percutaneous Coronary Intervention: Results From the HOST-EXAM Study
por: Hwang, Doyeon, et al.
Publicado: (2023)

Impact of the Dual Antiplatelet Therapy Score on Clinical Outcomes in Acute Coronary Syndrome Patients Receiving P2Y12 Inhibitor Monotherapy
por: Huang, Sheng-Wei, et al.
Publicado: (2022)

Meta-Analysis Comparing Potent Oral P2Y(12) Inhibitors versus Clopidogrel in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
por: Casula, Matteo, et al.
Publicado: (2020)

Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort
por: Obayashi, Yuki, et al.
Publicado: (2022)

ABCD‐GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILOR‐PCI Trial
por: Capodanno, Davide, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3fpn6ekgo5rph49hh5q0s5f4ce